1. Home
  2. SRRK vs CNO Comparison

SRRK vs CNO Comparison

Compare SRRK & CNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • CNO
  • Stock Information
  • Founded
  • SRRK 2012
  • CNO 1979
  • Country
  • SRRK United States
  • CNO United States
  • Employees
  • SRRK N/A
  • CNO N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • CNO Accident &Health Insurance
  • Sector
  • SRRK Health Care
  • CNO Finance
  • Exchange
  • SRRK Nasdaq
  • CNO Nasdaq
  • Market Cap
  • SRRK 4.2B
  • CNO 4.1B
  • IPO Year
  • SRRK 2018
  • CNO 1987
  • Fundamental
  • Price
  • SRRK $37.70
  • CNO $39.79
  • Analyst Decision
  • SRRK Strong Buy
  • CNO Hold
  • Analyst Count
  • SRRK 7
  • CNO 6
  • Target Price
  • SRRK $40.43
  • CNO $40.50
  • AVG Volume (30 Days)
  • SRRK 793.4K
  • CNO 588.8K
  • Earning Date
  • SRRK 02-27-2025
  • CNO 02-06-2025
  • Dividend Yield
  • SRRK N/A
  • CNO 1.61%
  • EPS Growth
  • SRRK N/A
  • CNO 55.83
  • EPS
  • SRRK N/A
  • CNO 3.74
  • Revenue
  • SRRK N/A
  • CNO $4,449,500,000.00
  • Revenue This Year
  • SRRK N/A
  • CNO N/A
  • Revenue Next Year
  • SRRK N/A
  • CNO $2.73
  • P/E Ratio
  • SRRK N/A
  • CNO $10.64
  • Revenue Growth
  • SRRK N/A
  • CNO 7.30
  • 52 Week Low
  • SRRK $6.76
  • CNO $24.92
  • 52 Week High
  • SRRK $46.98
  • CNO $42.02
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 41.93
  • CNO 48.33
  • Support Level
  • SRRK $35.35
  • CNO $40.44
  • Resistance Level
  • SRRK $38.61
  • CNO $42.02
  • Average True Range (ATR)
  • SRRK 1.80
  • CNO 0.84
  • MACD
  • SRRK -0.16
  • CNO -0.10
  • Stochastic Oscillator
  • SRRK 34.20
  • CNO 26.40

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About CNO CNO Financial Group Inc.

CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.

Share on Social Networks: